Clinical trials: Depressive
Depressive Disorder, Major, Suicidal
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in…
- Trial name
- NCT04669665
- Testing
- SLS-002, Standard of care, Intranasal device
- Where
- 21 sites in United States
- Volunteers
- 164 people
- Sponsor
- Seelos Therapeutics, Inc.
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Open Label Extension for GLYX13-C-202, NCT01684163
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
- Trial name
- NCT02192099
- Testing
- Rapastinel (225 mg/450 mg IV administration)
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder, Personality Disorder
Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial
Background: According to the WHO, major depressive disorder is the second largest healthcare problem worldwide in terms of disability caused by illness.
- Trial name
- Mipsy (NCT01070134)
- Testing
- Mindfulness-based Behavioural Therapy (MIBT), PT (psychodynamic therapy)
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Psychiatry Roskilde
Major Depressive Disorder (MDD)
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
- Trial name
- NCT06830044
- Testing
- Milsaperidone
- Where
- 53 sites in United States, Bulgaria and 2 more
- Volunteers
- 500 people
- Sponsor
- Vanda Pharmaceuticals
Depressive Disorder
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001
This is a phase 1, randomized, double-blind, placebo-controlled, SAD and MAD study in healthy adult volunteers. DGX-001 is a peptide being investigated for the treatment of the major depressive disorder.
- Trial name
- NCT05121831
- Testing
- DGX-001Dose 1, DGX-001 Dose 2, DGX-001 Dose 3
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Digestome Therapeutics
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01163266
- Testing
- Vortioxetine
- Where
- 39 sites in United States
- Volunteers
- 462 people
- Sponsor
- Takeda
Major Depressive Disorder
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06058039
- Testing
- NMRA-335140
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 422 people
- Sponsor
- Neumora Therapeutics, Inc.
Major Depressive Disorder
Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder
To compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with MDD.
- Trial name
- NCT00087737
- Testing
- DVS-233 SR, Venlafaxine ER
- Volunteers
- 369 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder
Bupropion & Cardio Birth Defect (Slone)
Bupropion is a unique drug that is used both to treat depression and as an aid in smoking cessation. In 2008, the final report from the Bupropion pregnancy registry described 24 congenital malformations among the 675 women…
- Trial name
- NCT01597661
- Testing
- Exposure to any bupropion during the first trimester, Exposure to bupropion alone during the first trimester, Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Depression, Major Depressive Disorder
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Depression
The purpose of this research study is to study closed-loop transcranial alternating current stimulation (tACS) to determine its effects on symptoms of depression in people with major depressive disorder.
- Conditions
- Depression, Major Depressive Disorder, tACS
- Trial name
- CLACS (NCT05772702)
- Testing
- Closed-loop tACS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Electromedical Products International, Inc.
Treatment Resistant Depression
Virtual Neuro-Navigation System for Personalized Community Based TMS
Phase I study of a virtual neuro-navigation package with built-in support for identifying specific "surface-based" targets to optimze TMS treatment.
- Trial name
- NCT04956081
- Testing
- Neuro-navigated Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Soterix Medical
Depressive Disorder
Seasonal Affective Depression (SAD) Study
A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
- Trial name
- NCT00069459
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Treatment Resistant Depression, Major Depressive Disorder
Clinical Study of GH001 in Depression
The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Depression
- Trial name
- NCT04698603
- Testing
- 5 Methoxy N,N Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- GH Research Ireland Limited
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Sexual Functioning Study With Antidepressants
Effects of two depression medication on sexual functioning
- Trial name
- NCT00316160
- Testing
- Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
- Where
- 45 sites in United States
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depressive Disorder, Major
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.
- Trial name
- NCT01564862
- Testing
- vortioxetine (Lu AA21004), Duloxetine
- Where
- 92 sites in United States, Bulgaria and 5 more
- Volunteers
- 602 people
- Sponsor
- Takeda
Major Depressive Disorder (MDD)
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
- Trial name
- NCT07226661
- Testing
- SPN-821 2400 mg
- Where
- 40 sites in United States
- Volunteers
- 230 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major…
- Trial name
- CLARITY (NCT07484217)
- Testing
- Solriamfetol 150 MG
- Where
- 40 sites in United States
- Volunteers
- 508 people
- Sponsor
- Axsome Therapeutics, Inc.